Pfizer Inc. PFE
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- +22.57%
- 1 year
- +25.65%
- Open
- 30.51
- Prev close
- 29.95
- Mkt cap
- 173.95B
- Vol
- 45.49M
- Avg vol
- 33.75M
- EPS
- 0.76
- P/E
- 40.16
- Div yield
- 5.74%
More statistics
- Low
- 30.14
- High
- 30.65
- Forward P/E
- 10.58
- Beta
- 0.28
- Short ratio
- 4.20
- Inst. own
- 69.06%
- Dividend
- 1.72
- Ex-div date
- Nov 5, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 28.49
- 200-d avg
- 26.77
- 1y target
- 29.26
5Y chart
Events in this range
- Nov 4, 2021Dividend: 0.39
- Jan 27, 2022Dividend: 0.4
- May 12, 2022Dividend: 0.4
- Jul 28, 2022Dividend: 0.4
- Nov 3, 2022Dividend: 0.4
- Dec 5, 2022Dividend: 0.4
- Jan 26, 2023Dividend: 0.41
- May 11, 2023Dividend: 0.41
- Jul 27, 2023Dividend: 0.41
- Nov 9, 2023Dividend: 0.41
- Nov 10, 2023Dividend: 0.41
- Jan 25, 2024Dividend: 0.42
- Jan 26, 2024Dividend: 0.42
- May 9, 2024Dividend: 0.42
- Jul 25, 2024Dividend: 0.42
- Jul 26, 2024Dividend: 0.42
- Nov 8, 2024Dividend: 0.42
- Jan 24, 2025Dividend: 0.43
- May 9, 2025Dividend: 0.43
- Jul 25, 2025Dividend: 0.43
- Aug 5, 2025Earnings: 0.78; estimate 0.58; surprise 34.48%
- Nov 4, 2025Earnings: 0.87; estimate 0.633; surprise 37.44%
- Nov 7, 2025Dividend: 0.43
- Jan 23, 2026Dividend: 0.43
- Feb 3, 2026Earnings: 0.66; estimate 0.567; surprise 16.4%
- May 5, 2026Earnings: 0.75; estimate 0.722; surprise 3.88%
- May 8, 2026Dividend: 0.43
- Jul 13, 2026Rating: BMO Capital · Outperform → Outperform
- Jul 24, 2026Dividend: 0.43
- Aug 4, 2026Earnings: 0.77; estimate 0.682; surprise 12.9%
- Aug 7, 2026Rating: Guggenheim · Buy → Buy
- Sep 10, 2026Rating: HSBC · Hold → Hold
- Oct 6, 2026Rating: Scotiabank · Sector Outperform → Sector Outperform
- Oct 8, 2026Rating: Cantor Fitzgerald · Neutral → Neutral
- Oct 9, 2026Rating: JP Morgan · Neutral → Neutral
- Nov 3, 2026Earnings: —; estimate 0.729; surprise —%
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 22, 2025 | 10 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 17, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 1, 2024 | 2 years ago |
| RSI: Oversold | Nov 27, 2023 | 2 years ago |
| RSI: Oversold | Nov 6, 2023 | 2 years ago |
| RSI: Oversold | Oct 9, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| RSI: Oversold | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 5, 2023 | 3 years ago |
| RSI: Oversold | May 8, 2023 | 3 years ago |
| RSI: Oversold | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 23, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
| SMA: Bullish | May 16, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 173.87B
- Enterprise value
- 222.78B
- Trailing P/E
- 40.14
- Forward P/E
- 10.58
- PEG ratio
- 13.72
- Price / sales
- 2.73
- Price / book
- 2.04
- EPS (TTM)
- 0.76
- Beta
- 0.28
- Dividend yield
- 5.74%
- Payout ratio
- 226.32%
- Profit margin
- 6.80%
- Revenue (TTM)
- 63.70B
- Revenue growth
- 2.60%
- Free cash flow
- 12.49B
- Total cash
- 11.70B
- Total debt
- 63.48B
- Return on equity
- 5.01%
- Shares outstanding
- 5.70B
- Short % of float
- 2.42%
- 50-day average
- 28.49
- 200-day average
- 26.77
Analyst view
Consensus: buy
- Target (low)
- 25.00
- Target (mean)
- 29.26
- Target (high)
- 36.00
- Strong buy1
- Buy8
- Hold17
- Sell1
- Strong sell1
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.72803.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 28, 2026 | 0.729 | — | — | — |
| Aug 4, 2026 | Jun 28, 2026 | 0.682 | 0.77 | +0.09 | +12.90% |
| May 5, 2026 | Mar 29, 2026 | 0.722 | 0.75 | +0.03 | +3.88% |
| Feb 3, 2026 | Dec 31, 2025 | 0.567 | 0.66 | +0.09 | +16.40% |
| Nov 4, 2025 | Sep 28, 2025 | 0.633 | 0.87 | +0.24 | +37.44% |
| Aug 5, 2025 | Jun 29, 2025 | 0.58 | 0.78 | +0.20 | +34.48% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 6, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | main | Hold | Hold |
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| Jul 13, 2026 | BMO Capital | main | Outperform | Outperform |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- pfizer.com
News
- Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
- Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
- Pfizer: Reality Check Ahead Of Earnings
- Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?
- GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
- Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
- Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
- Are Your Dividends Safe? 4 Yields That Are High for the Wrong Reason
- Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3
Your note
Sign in to keep a note on PFE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLAYLOCK RONALD E | Director | Purchase | Aug 4, 2026 | 71,688 |
| BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) | Feb 24, 2026 | 162,088 |
| BOURLA ALBERT | Chief Executive Officer | Purchase | Aug 11, 2026 | 435,555 |
| BUCKLEY MORTIMER J. | Director | Purchase | Aug 4, 2026 | 37,632 |
| DAMICO JENNIFER B. | Officer | Sale | Aug 4, 2026 | 28,611 |
| FONSECA LIDIA PH.D. | Officer | Conversion of Exercise of derivative security | Feb 24, 2026 | 46,455 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.29% | 529,670,433 | 16.16B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 372,149,852 | 11.35B | Jun 29, 2026 |
| State Street Corporation | 5.39% | 307,090,897 | 9.37B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.37% | 135,275,782 | 4.13B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.09% | 119,235,030 | 3.64B | Jun 29, 2026 |
| Fisher Asset Management, LLC | 1.91% | 109,067,291 | 3.33B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 180,944,898 | 5.52B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 147,700,066 | 4.51B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 75,946,889 | 2.32B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 73,983,903 | 2.26B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 70,581,611 | 2.15B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.95% | 54,248,096 | 1.65B | Jun 29, 2026 |